benzyl 4-(piperidine-4-carbonyl)piperazine-1-carboxylate | 1221567-08-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 4-(piperidine-4-carbonyl)piperazine-1-carboxylate
• 英文别名: 4-(piperidine-4-carbonyl)piperazine-1-carboxylic acid benzyl ester
• CAS: 1221567-08-3
• 化学式: C₁₈H₂₅N₃O₃
• 分子量: 331.415
• InChiKey: RLYAUQDCYKXWTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl 4-(piperidine-4-carbonyl)piperazine-1-carboxylate 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 32.0h， 生成 benzyl 4-[1-[(1-tert-butoxycarbonylazetidin-3-yl)methyl]-1-(2-tert-butoxy-2-oxoethyl)piperidin-1-ium-4-carbonyl]piperazine-1-carboxylate formate
  参考文献：
  名称：

  [EN] QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS À SUBSTITUTION PAR CATIONS AMMONIUM QUATERNAIRES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES

  摘要：

  The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1to R6are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

  公开号：

  WO2023280733A1
• 作为产物：
  描述：

  1-Boc-4-哌啶甲酸 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 benzyl 4-(piperidine-4-carbonyl)piperazine-1-carboxylate
  参考文献：
  名称：

  1, 4-二杂环基取代芳环或芳杂环类化合物及其应用

  摘要：

  本发明公开了式(I)所示的1,4‑二杂环基取代芳环或芳杂环类化合物，该化合物能够有效抑制20‑HETE的生成，并且具有高活性、高选择性、良好的药代动力学特性，通过抑制20‑HETE的生成，可用于治疗与20‑HETE相关的多种疾病，有较大的应用价值。

  公开号：

  CN116615417A

文献信息

• [EN] PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS À BASE DE PYRIDINE ET DE PYRIMIDINE EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT POUR LE TRAITEMENT DU CANCER
  申请人：CANCER REC TECH LTD

  公开号：WO2010041054A1

  公开（公告）日：2010-04-15

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and / or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物，以及它们作为治疗和/或预防癌症的潜在用途。
• PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：McDonald Edward

  公开号：US20110190297A1

  公开（公告）日：2011-08-04

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物，包括这些化合物的药物组合物以及它们作为治疗和/或预防癌症的治疗剂的潜在用途。
• Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer
  申请人：McDonald Edward

  公开号：US08778925B2

  公开（公告）日：2014-07-15

  The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.

  本发明涉及以吡啶和嘧啶为基础的化合物、包含这些化合物的药物组合物以及它们作为治疗和/或预防癌症的潜在治疗剂的用途。
• US8778925B2
  申请人：——

  公开号：US8778925B2

  公开（公告）日：2014-07-15
• METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D)
  申请人：[en]RANOK THERAPEUTICS (HANGZHOU) CO. LTD.

  公开号：WO2024044334A2

  公开（公告）日：2024-02-29

  Provided are tumor- targeted protein degradation chimeras, termed chaperone- mediated protein degraders (CHAMPs) comprising a first moiety that is capable of binding to a target protein (e.g., KRAS(G12D) or proteins and a second moiety that is capable of binding a chaperone protein or proteins or protein component of chaperone complexes (e.g., HSP90). Pharmacetuical compositions comprising the disclosed CHAMPs and their uses for treating thereof, which are useful for treating cancers and related conditions are also provided.